HDAC9 and nasopharyngeal carcinoma: We have previously reported that the CLVA drug regimen (combined use of GCb and VPA; an FDA approved nucleoside analog and HDAC inhibitor), significantly and synergistically reactivates the latent virus in NPC tumor cells into the lytic replicative phase both in vitro and in vivo and applied this strategy in a clinical Phase-I/-II trial with promising clinical responses [5,6,7].